Aliases & Classifications for Spasticity

MalaCards integrated aliases for Spasticity:

Name: Spasticity 51 29

Summaries for Spasticity

NINDS : 51 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might  interfere with movement, speech, or be associated with discomfort or pain.  Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may occur in association with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders, and often interferes with daily activities.

MalaCards based summary : Spasticity is related to spastic paraplegia 13 and vitamin b12 deficiency. An important gene associated with Spasticity is DARS (Aspartyl-TRNA Synthetase). The drugs Acetylcholine and Baclofen have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and t cells.

Wikipedia : 72 Spasticity (from Greek spasmos-, meaning \'drawing, pulling\') is a feature of altered skeletal muscle... more...

Related Diseases for Spasticity

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 720)
id Related Disease Score Top Affiliating Genes
1 spastic paraplegia 13 32.5 DDHD1 KIF1A TECPR2
2 vitamin b12 deficiency 29.1 SLC1A4 SLC2A1
3 spinocerebellar degeneration 29.0 MECP2 SLC2A1
4 hereditary spastic paraplegia 12.3
5 tropical spastic paraparesis 12.2
6 spastic paraplegia 2, x-linked 12.2
7 spastic paraplegia 7, autosomal recessive 12.2
8 spastic hemiplegia 12.1
9 spastic diplegia 12.1
10 silver spastic paraplegia syndrome 12.1
11 spastic quadriplegia 12.1
12 spastic paraplegia 23 12.1
13 spastic paraplegia 11, autosomal recessive 12.1
14 spastic paraplegia 35, autosomal recessive 12.1
15 spastic paraplegia 15, autosomal recessive 12.1
16 spastic paraplegia 11 12.1
17 spastic paraplegia 4 12.1
18 spastic paraplegia 9a, autosomal dominant 12.1
19 spastic paraplegia 39, autosomal recessive 12.1
20 spastic paraplegia 54, autosomal recessive 12.1
21 spastic paraplegia 4, autosomal dominant 12.0
22 spastic cerebral palsy 12.0
23 spastic paraplegia 49, autosomal recessive 12.0
24 spastic paraplegia, optic atrophy, and neuropathy 12.0
25 infantile-onset ascending hereditary spastic paralysis 12.0
26 spastic paraplegia 43, autosomal recessive 12.0
27 spastic paraplegia 72, autosomal recessive 12.0
28 spastic paraplegia 30, autosomal recessive 12.0
29 spastic paraplegia 56, autosomal recessive 12.0
30 spastic paraplegia 5a, autosomal recessive 12.0
31 spastic paraplegia 8, autosomal dominant 12.0
32 spastic paraplegia 10, autosomal dominant 12.0
33 spastic paraplegia 6, autosomal dominant 12.0
34 spastic paraplegia 53, autosomal recessive 12.0
35 spastic paraplegia 26, autosomal recessive 12.0
36 spastic paraplegia 12, autosomal dominant 12.0
37 spastic paraplegia 48, autosomal recessive 12.0
38 spastic paraplegia 28, autosomal recessive 12.0
39 troyer syndrome 12.0
40 spastic paraplegia 45, autosomal recessive 12.0
41 spastic paraplegia 57, autosomal recessive 12.0
42 spastic paraplegia 18, autosomal recessive 12.0
43 spastic paraplegia 46, autosomal recessive 12.0
44 spastic paraplegia 55, autosomal recessive 12.0
45 spastic paraplegia 8 12.0
46 spastic paraplegia 75, autosomal recessive 12.0
47 spastic paraplegia 61, autosomal recessive 12.0
48 spastic paraplegia 77, autosomal recessive 12.0
49 spastic paraplegia 31, autosomal dominant 12.0
50 spastic paraplegia 42, autosomal dominant 12.0

Graphical network of the top 20 diseases related to Spasticity:



Diseases related to Spasticity

Symptoms & Phenotypes for Spasticity

Drugs & Therapeutics for Spasticity

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 284)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 51-84-3 187
2
Baclofen Approved Phase 4,Phase 3,Phase 1,Phase 2 1134-47-0 2284
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Levodopa Approved Phase 4 59-92-7 6047
5
Memantine Approved, Investigational Phase 4 19982-08-2 4054
6
Tizanidine Approved Phase 4,Phase 3,Phase 1,Phase 2 51322-75-9 5487
7
Dronabinol Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 1972-08-3 16078 2978
8
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
9 Peppermint oil Approved Phase 4,Phase 3
10 Piracetam Approved Phase 4,Phase 2 7491-74-9
11
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
12
Clonidine Approved Phase 4,Phase 3,Phase 1,Phase 2 4205-90-7 2803
13
Norepinephrine Approved Phase 4 51-41-2 439260
14
Lidocaine Approved, Vet_approved Phase 4,Phase 2 137-58-6 3676
15
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
16
Peppermint Approved, Nutraceutical Phase 4,Phase 3
17
gamma-Aminobutyric acid Investigational Phase 4 56-12-2 119
18 Etiracetam Investigational Phase 4,Phase 2 33996-58-6
19 abobotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
20 Botulinum Toxins Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
21 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
22 Cholinergic Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
23 incobotulinumtoxinA Phase 4,Phase 3,Phase 2
24 Neuromuscular Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
25 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
26 onabotulinumtoxinA Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
27 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
28 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Carbidopa, levodopa drug combination Phase 4
30 Dihydroxyphenylalanine Phase 4
31 Dopamine Agents Phase 4
32 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Adrenergic Agents Phase 4,Phase 3,Phase 1,Phase 2
34 Analgesics Phase 4,Phase 3,Phase 2,Phase 1
35 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2
36 Antiparkinson Agents Phase 4,Phase 1
37 Excitatory Amino Acid Antagonists Phase 4,Phase 2
38 Excitatory Amino Acids Phase 4,Phase 2
39 Neuroprotective Agents Phase 4,Phase 3,Phase 2,Phase 1
40 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
41 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
42 Antidepressive Agents Phase 4,Phase 1,Phase 2
43 Neurotransmitter Uptake Inhibitors Phase 4,Phase 1
44 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
45 calcium channel blockers Phase 4,Phase 3
46 Calcium, Dietary Phase 4,Phase 3,Phase 2
47 GABA Agents Phase 4,Phase 3,Phase 2,Phase 1
48 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Adrenergic Agonists Phase 4,Phase 3,Phase 1,Phase 2
50 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 3,Phase 1,Phase 2

Interventional clinical trials:

(show top 50) (show all 632)

id Name Status NCT ID Phase Drugs
1 The Effectiveness of Early Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
2 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
3 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Unknown status NCT02358005 Phase 4
4 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
5 Effects of Functional Electrical Stimulation on Gait in Children With Cerebral Palsy Unknown status NCT02462018 Phase 4
6 The Efficacy and Safety of MEDITOXIN® in Children With Cerebral Palsy Unknown status NCT01256021 Phase 4 Botulinum Toxin Type A
7 Does Oral Baclofen Improve Care and Comfort in Spastic Children in Nursing Homes? Unknown status NCT00752934 Phase 4 oral baclofen + placebo;placebo + oral baclofen
8 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
9 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
10 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
11 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
12 SISTERS: Spasticity In Stroke Study - Randomized Study Completed NCT01032239 Phase 4 intrathecal baclofen
13 Safety of Xeomin for Lower Limb Spasticity in Multiple Sclerosis Patients Completed NCT01968902 Phase 4
14 Asian Botulinum Clinical Trial Designed for Early Stroke Spasticity Completed NCT00234546 Phase 4 Botulinum toxin type A (Dysport®)
15 Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression Completed NCT02321436 Phase 4 BotulinumtoxinA;Placebo
16 BOTOX® Versus Zanaflex® for the Treatment of Post-Stroke or Traumatic Brain Injury Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
17 Effects on Quality of Life Following Dysport Treatment in Post-Stroke Spasticity of the Arm Completed NCT00216411 Phase 4 Botulinum type A toxin (Dysport)
18 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
19 Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
20 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
21 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
22 A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients Completed NCT01964547 Phase 4 Sativex;Placebo
23 Spread And Effectiveness Of Botulinum Neurotoxin A In Spastic Equinus In Cerebral Palsy Completed NCT01276015 Phase 4 Botulinum Toxin Type A
24 Botulinum Toxin A Adult Gastrocnemius Muscle Study Completed NCT01278576 Phase 4 BOTOX-A®
25 SynchroMed II Post-Approval Study Completed NCT00773019 Phase 4
26 Recurrent Crying Spells in Cerebral Palsy Completed NCT01955655 Phase 4 Baclofen
27 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
28 Τhe Effectiveness of Hydrotherapy Exercises on the Rehabilitation of Hemiplegic Patients Completed NCT01460277 Phase 4
29 Levetiracetam in Chronic Neuropathic Pain Following Spinal Cord Injury Completed NCT00252954 Phase 4 Levetiracetam
30 Tizanidine and Superficial Cervical Block on Pain After Thyroidectomy Completed NCT02725359 Phase 4 Placebo;Tizanidine;Bupivacaine;Saline
31 Investigating Botulinum Toxin A to Treat Acute Neck/Upper Shoulder Pain Following a New Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
32 Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
33 Project to Improve Symptoms and Mood in People With Spinal Cord Injury Completed NCT00592384 Phase 4 venlafaxine XR;placebo
34 Post Marketing Surveillance Study of Dysport Completed NCT00210431 Phase 4
35 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
36 Intrathecal Baclofen (ITB) Delivery Location and Its Effect on Spasticity Recruiting NCT02903823 Phase 4 Baclofen bolus injection
37 Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC) Recruiting NCT02969356 Phase 4 AbobotulinumtoxinA (Dysport®)
38 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
39 Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Recruiting NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
40 Upper Limb Botulinum Toxin Injection Combined With Self Rehabilitation Recruiting NCT02699762 Phase 4
41 Treatment for Alcohol Dependence With Gabapentin Recruiting NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
42 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
43 Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity Not yet recruiting NCT02757404 Phase 4
44 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface EMG Recordings Not yet recruiting NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
45 The Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke Not yet recruiting NCT02944929 Phase 4
46 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing Dynamic Hand Splinting in Adults With Post-stroke Hemiplegia (Orthox) Not yet recruiting NCT02888548 Phase 4
47 Improvement After Botulinum Toxin Injections to the Arms in Children With Cerebral Palsy Terminated NCT00549471 Phase 4
48 Efficacy of Botulinum Toxin Versus Lidocaine in Treating Masticatory Myofascial Face Pain Using Ultrasound and EMG Guided Techniques Terminated NCT00992108 Phase 4 lidocaine;chemodenervation
49 Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke Unknown status NCT01910363 Phase 2, Phase 3 A2NTX;BOTOX
50 Botulinim Toxin Type A Injections by Different Guidance in Stroke Patients With Spasticity on Lower Extremities Unknown status NCT02469948 Phase 3 Botulinum toxin type A

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

Genetic tests related to Spasticity:

id Genetic test Affiliating Genes
1 Spasticity 29

Anatomical Context for Spasticity

MalaCards organs/tissues related to Spasticity:

39
Spinal Cord, Brain, T Cells, Testes, Bone, Skeletal Muscle, Cortex

Publications for Spasticity

Articles related to Spasticity:

(show top 50) (show all 3295)
id Title Authors Year
1
Selective dorsal rhizotomy: A multidisciplinary approach to treating spastic diplegia. ( 28761524 )
2017
2
Considering Spastic Paraplegia Type 7 and Adult-Onset Alexander Disease. ( 28459923 )
2017
3
Effects of an Off-Axis Pivoting Elliptical Training Program on Gait Function in Persons With Spastic Cerebral Palsy: A Preliminary Study. ( 28628539 )
2017
4
Influence of transcutaneous electrical nerve stimulation on spasticity, balance, and walking speed in stroke patients: A systematic review and meta-analysis. ( 28862711 )
2017
5
A Novel Homozygous SACS Mutation Identified by Whole-Exome Sequencing in a Consanguineous Family with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. ( 28658676 )
2017
6
Co-existence of spastic paraplegia-30 with novel KIF1A mutation and spinocerebellar ataxia 31 with intronic expansion of BEAN and TK2 in a family. ( 28017198 )
2017
7
Genetic dissection of oligodendroglial and neuronal Plp1 function in a novel mouse model of spastic paraplegia type 2. ( 28836307 )
2017
8
SPG20 mutation in three siblings with familial hereditary spastic paraplegia. ( 28679690 )
2017
9
Structured skill practice during intensive bimanual training leads to better trunk and arm control than unstructured practice in children with unilateral spastic cerebral palsy. ( 27912104 )
2017
10
TFG associated hereditary spastic paraplegia: an addition to the phenotypic spectrum. ( 28124177 )
2017
11
Febrile ataxia and myokymia broaden the SPG26 hereditary spastic paraplegia phenotype. ( 28626794 )
2017
12
Identification of novel SPG11 mutations in a cohort of Chinese families with hereditary spastic paraplegia. ( 28933964 )
2017
13
Antibody responses to botulinum neurotoxin type A of toxin-treated spastic equinus children with cerebral palsy: A randomized clinical trial comparing two injection schedules. ( 28385185 )
2017
14
A Middle-aged Man With Progressive Ophthalmoparesis, Ataxia, and Spastic Paraparesis. ( 28437518 )
2017
15
Ixcellence NetworkAr: an international educational network to improve current practice in the management of cervical dystonia or spastic paresis by botulinum toxin injection. ( 28676144 )
2017
16
Progressive hereditary spastic paraplegia caused by a homozygous KY mutation. ( 28488683 )
2017
17
ATPase-deficient mitochondrial inner membrane protein ATAD3A disturbs mitochondrial dynamics in dominant hereditary spastic paraplegia. ( 28158749 )
2017
18
Cortical bone deficit and fat infiltration of bone marrow and skeletal muscle in ambulatory children with mild spastic cerebral palsy. ( 27732905 )
2017
19
Computer-based assessment of upper-limb incoordination in autosomal recessive spastic ataxia of Charlevoix-Saguenay patients: A pilot study. ( 28870592 )
2017
20
Long-term therapy with intrathecal baclofen improves quality of life in children with severe spastic cerebral palsy. ( 28237420 )
2017
21
PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia. ( 28295203 )
2017
22
De novo REEP2 missense mutation in pure hereditary spastic paraplegia. ( 28491902 )
2017
23
Evaluating treatment options for spasticity. ( 28914442 )
2017
24
Novel UBQLN2 mutations linked to amyotrophic lateral sclerosis and atypical hereditary spastic paraplegia phenotype through defective HSP70-mediated proteolysis. ( 28716533 )
2017
25
Targeted high throughput sequencing in hereditary ataxia and spastic paraplegia. ( 28362824 )
2017
26
Spasticity may obscure motor learning ability after stroke. ( 28904099 )
2017
27
Hypomorphic mutations in POLR3A are a frequent cause of sporadic and recessive spastic ataxia. ( 28459997 )
2017
28
Immediate effects of quick trunk movement exercise on sit-to-stand movement in children with spastic cerebral palsy: a pilot study. ( 28603369 )
2017
29
ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia. ( 27738760 )
2017
30
Patterns of botulinum toxin treatment for spasticity and bleeding complications in patients with thrombotic risk. ( 28919457 )
2017
31
A simple tool to measure spasticity in spinal cord injury subjects. ( 28814047 )
2017
32
Beneficial effects of rapamycin in a Drosophila model for hereditary spastic paraplegia. ( 27909242 )
2017
33
Correspondence: Skeletal Maturation and Mineralization of Children with Moderate to Severe Spastic Quadriplegia. ( 28571225 )
2017
34
IL17A Polymorphism Is Not Associated with Human T-Lymphotropic Virus 1-Associated Myelopathy/Tropical Spastic Paraparesis. ( 28410448 )
2017
35
Spastic paraplegia type 4: A novel SPAST splice site donor mutation and expansion of the phenotype variability. ( 28870597 )
2017
36
Purkinje Cell Degeneration and Motor Coordination Deficits in a New Mouse Model of Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay. ( 28588446 )
2017
37
Effect of neurodevelopmental treatment-based physical therapy on the change of muscle strength, spasticity, and gross motor function in children with spastic cerebral palsy. ( 28626301 )
2017
38
Clinical Neuropathology teaching case 2-2017: polymicrogyria in an adult with right-sided spastic hemiparesis. ( 28220750 )
2017
39
Increased lower limb muscle coactivation reduces gait performance and increases metabolic cost in patients with hereditary spastic paraparesis. ( 28779695 )
2017
40
Neurophysiological mechanisms and functional impact of mirror movements in children with unilateral spastic cerebral palsy. ( 28884806 )
2017
41
Different Effects of Cold Stimulation on Reflex and Non-Reflex Components of Poststroke Spastic Hypertonia. ( 28503163 )
2017
42
Mediators Go Together: High Production of CXCL9, CXCL10, IFN-I^, and TNF-I+ in HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. ( 28648091 )
2017
43
Mutations in NKX6-2 Cause Progressive Spastic Ataxia and Hypomyelination. ( 28575651 )
2017
44
Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities. ( 28393669 )
2017
45
Stretch-reflex threshold modulation during active elbow movements in post-stroke survivors with spasticity. ( 28826019 )
2017
46
Structural annotation of Beta-1,4-N-acetyl galactosaminyltransferase 1 (B4GALNT1) causing Hereditary Spastic Paraplegia 26. ( 28536081 )
2017
47
Transient Changes in Brain Metabolites after Transcranial Direct Current Stimulation in Spastic Cerebral Palsy: A Pilot Study. ( 28824525 )
2017
48
Novel mutations c. [453dupA] + [663G > A] of the SPG11 gene associated with hereditary spastic paraplegia with a thin corpus callosum. ( 28681766 )
2017
49
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP). ( 28095504 )
2017
50
Large Intragenic Deletion in DSTYK Underlies Autosomal-Recessive Complicated Spastic Paraparesis, SPG23. ( 28157540 )
2017

Variations for Spasticity

Expression for Spasticity

Search GEO for disease gene expression data for Spasticity.

Pathways for Spasticity

GO Terms for Spasticity

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 postsynapse GO:0098794 8.65 MECP2
2 axon cytoplasm GO:1904115 8.62 KIF1A SPG7

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 8.62 KIF1A SPG7

Sources for Spasticity

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....